Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-1/A IPO registration
- 1.1 Form of Underwriting Agreement
- 4.1 Form of Xcyte Therapies, Inc. Stock Certificate.
- 5.1 Opinion of Heller Ehrman White & Mcauliffe LLP.
- 10.18 Warrant to Purchase Series F Preferred Stock Dated November 7, 2003.
- 10.19 Warrant to Purchase Series F Preferred Stock Dated December 19, 2003.
- 10.26 Third Amendment to Lease Dated November 12, 2003.
- 10.32 License and Supply Agreement with Diaclone S.a., As Amended.
- 10.33 First Amendment to License and Supply Agreement with Diaclone S.a.
- 10.34 Development and Supply Agreement with Dynal S.a.
- 10.35 License Agreement with Genetics Institute, Inc. Dated July 8, 1998.
- 10.36 First Amendment to License Agreement with Genetics Institute, Inc.
- 10.37 Non-exclusive License Agreement with the Fred Hutchinson Cancer Research Center.
- 10.38 Services Agreement with Lonza Biologics PLC, Dated June 6, 2000.
- 10.44 Services Agreement with Lonza Biologics PLC, Dated June 6, 2000.
- 10.47 Collaboration Agreement with Fresenius Biotech GMBH Dated November 14, 2003.
- 10.50 Employment Agreement with Robert L. Kirkman Dated January 15, 2004.
- 23.1 Consent of Ernst & Young LLP, Independent Auditors.
CYCC similar filings
Filing view
External links
Exhibit 23.1
Consent of Ernst & Young LLP, Independent Auditors
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated January 23, 2004 (except for the first paragraph of Note 13, as to which the date is February XX, 2004), in Amendment No. 2 to the Registration Statement (Form S-1 No. 333-109653) and related Prospectus of Xcyte Therapies, Inc. for the registration of 4,600,000 shares of its common stock.
Ernst & Young LLP
Seattle, Washington
February XX, 2004
The foregoing consent is in the form that will be signed upon the completion of reverse stock split, described in Note 13 to the financial statements.
/s/ Ernst & Young LLP
Seattle, Washington
February 13, 2004